Drug Trial Radar · NCT04784715
Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)
Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,157
Actual
Start
Apr 26, 2021
Primary completion
May 3, 2027
Study completion Dec 31, 2029
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Daiichi Sankyo
- First posted
- Mar 5, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 130 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study will evaluate the efficacy and safety of trastuzumab deruxtecan (also known as T-DXd, DS-8201a), either alone or in combination with pertuzumab, in treating patients with Human epidermal growth factor receptor 2 (HER2)-positive breast cancer as a first line of treatment in the metastatic setting.
Conditions
- Breast Cancer; HER2-positive; Metastatic
Interventions
Trastuzumab deruxtecanDrug
Administered by intravenous infusion
PlaceboDrug
Administered by intravenous infusion
TaxaneDrug
Investigator's choice of docetaxel or paclitaxel administered by intravenous infusion
PertuzumabDrug
Administered by intravenous infusion
TrastuzumabDrug
Administered by intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) assessmentTime frame: Until progression or death, assessed up to approximately 60 months
Locations
283 sites in 27 countries. Site status is shown where the registry gives one.
Research Site
Tucson, Arizona
Research Site
Springdale, Arkansas
Research Site
Glendale, California
Research Site
Glendale, California
Research Site
Longmont, Colorado
Research Site
Miami, Florida
Research Site
Palm Bay, Florida
Research Site
Plantation, Florida
Research Site
Atlanta, Georgia
Research Site
Louisville, Kentucky
Research Site
Silver Spring, Maryland
Research Site
Boston, Massachusetts
Research Site
Detroit, Michigan
Research Site
Jackson, Mississippi
Research Site
Las Vegas, Nevada
Research Site
Summit, New Jersey
Research Site
New York, New York
Research Site
Shirley, New York
Research Site
York, Pennsylvania
Research Site
Germantown, Tennessee
Research Site
Dallas, Texas
Research Site
Dallas, Texas
Research Site
Denton, Texas
Research Site
Houston, Texas
Research Site
San Antonio, Texas
Research Site
Shenandoah, Texas
Research Site
Tyler, Texas
Research Site
Norfolk, Virginia
Research Site
Roanoke, Virginia
Research Site
Tacoma, Washington
Research Site
Buenos Aires, Argentina
Research Site
Caba, Argentina
Research Site
CABA, Argentina
Research Site
CABA, Argentina
Research Site
Capital Federal, Argentina
Research Site
Cipolletti, Argentina
Research Site
Ciudad de Buenos Aires, Argentina
Research Site
La Plata, Argentina
Research Site
Mar del Plata, Argentina
Research Site
Rosario, Argentina
Showing 40 of 283 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.